342 results on '"Masarone, Mario"'
Search Results
2. The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition
3. Artificial Intelligence and liver: Opportunities and barriers
4. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
5. WED-326 Effects of weight loss on overweight or obese MASLD patients after six months of dieting
6. WED-333 Association of clinical and biochemical parameters and polygenic risk score in a metabolic steatosis population of southern Italy
7. FRI-281 Metabolic steatosis in renal transplant recipients does not correlate with CVD, a retrospective cohort study
8. Gut–Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers
9. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
10. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
11. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
12. Italian association for the study of the liver position statement on SARS-CoV2 vaccination
13. Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review.
14. Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver
15. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program
16. From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
17. Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience
18. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort
19. Artificial Intelligence and liver: Opportunities and barriers
20. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort
21. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis
22. A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report
23. Detecting early improvements in a NAFLD patient population during diet-induced weight loss
24. Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy
25. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study
26. Urinary L-FABP: a potential novel early biomarker for Diabetic Nephropathy? A systematic review of the literature
27. Corrigendum to ‘Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)’ Nutrition, Metabolism and Cardiovascular diseases volume 32 issue 1 (2022) 1-16
28. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
29. Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate—a pilot study
30. Corrigendum to “Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)” [Dig Liver Dis 54 (2022) 170–182]
31. HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?
32. Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by peripheral arterial tonometry in non-alcoholic fatty liver disease
33. Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
34. Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkinʼs lymphoma
35. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori
36. Lung ultrasound for diagnosis of pneumonia in emergency department
37. Screening for hepatitis C at the time of the pandemic: Need to adjust the shot
38. Efficacy and Safety of a Polysaccharide-Based Natural Substance Complex in the Treatment of Obesity and Other Metabolic Syndrome Components: A Systematic Review
39. Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic
40. Hepatitis C screening during SARS‐CoV ‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno
41. A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
42. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
43. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
44. Solving the Gap Between HCV Detection and Treatment in Prison HCVRNA Testing and Treatment in a Cohort of Newly Arrived Convicts in Southern Italy
45. PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial
46. Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by Peripheral Arterial Tonometry in Non Alcoholic Fatty Liver Disease
47. Associated screening for HCV and SARS‐Cov2 infection in an urban area of Southern Italy: a cohort study
48. Corrigendum to “Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease”
49. Viral hepatitis: Milestones, unresolved issues, and future goals
50. A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.